search
Back to results

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PREVAIL)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Basal insulin and exenatide
Basal insulin only
Basal insulin and bolus insulin
Sponsored by
Mount Sinai Hospital, Canada
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring type 2 diabetes, beta-cell function, GLP-1, insulin

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Men and women between the ages of 30 and 80 years inclusive
  2. T2DM diagnosed by a physician ≤7 years prior to enrolment
  3. On 0-2 anti-diabetic medications, with no change in dose/regimen in the preceding 4 weeks
  4. A1c at screening between 5.5% and 9.0% inclusive if on anti-diabetic medications, or between 6.0% and 9.5% inclusive if on no oral anti-diabetic medication
  5. BMI ≥ 23 kg/m2
  6. Negative pregnancy test at recruitment for all women with childbearing potential

Exclusion Criteria:

  1. Current anti-diabetic treatment with insulin or a glucagon-like peptide-1 (GLP-1) agonist
  2. Type 1 diabetes or secondary forms of diabetes
  3. History of hypoglycemia unawareness or severe hypoglycemia requiring assistance
  4. Hypersensitivity to insulin, exenatide, or the formulations of these products
  5. Renal dysfunction as evidenced by estimated glomerular filtration rate (eGFR)<30 ml/min by Modification of Diet in Renal Disease (MDRD) formula
  6. History of pancreatitis
  7. Family or personal history of Multiple Endocrine Neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma (MTC)
  8. Personal history of non-familial medullary thyroid carcinoma (MTC)
  9. Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)
  10. Unwillingness to perform capillary glucose monitoring at least 4 times a day during treatment
  11. Pregnancy or unwillingness to use reliable contraception. Women should not be planning pregnancy for the duration of the study or the first 3 months after the study. Reliable contraception includes birth control pill, intra-uterine device, abstinence, tubal ligation, partner vasectomy, or condoms with spermicide.
  12. Any factor likely to limit adherence to the protocol, in the opinion of investigator

Sites / Locations

  • Mount Sinai Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Basal insulin and exenatide

Basal insulin only

Basal Insulin and bolus insulin

Arm Description

Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.

Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.

Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.

Outcomes

Primary Outcome Measures

Mean beta-cell function over the 8-week treatment period, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2)
ISSI-2 is an established measure of beta-cell function. ISSI-2 is defined as the product of (i) insulin secretion measured by the ratio of the area-under-the-insulin-curve to the area-under-the-glucose curve and (ii) insulin sensitivity measured by the Matsuda index. The primary outcome comparison is between the glargine/exenatide and glargine only arms.

Secondary Outcome Measures

Baseline-adjusted beta-cell function at 20 weeks
The secondary outcome of baseline-adjusted beta-cell function at 20 weeks will be measured with the Insulin Secretion-Sensitivity Index-2 (ISSI-2)
Baseline-adjusted glycemic control at 20 weeks
The secondary outcome of baseline-adjusted glycemic control at 20 weeks will be assessed by A1c (glycated hemoglobin)
Endothelial function at 8 weeks
Endothelial function will be assessed as the digital endothelial vasomotor function in response to reactive hyperemia using pulse amplitude tonometry, which will be measured by the pulse amplitude response to hyperemia (PAT ratio)
Baseline-adjusted glycemic control at 8 weeks
Baseline-adjusted glycemic control at 8 weeks will be measured by A1c

Full Information

First Posted
July 16, 2014
Last Updated
April 7, 2022
Sponsor
Mount Sinai Hospital, Canada
Collaborators
Canadian Institutes of Health Research (CIHR), University of Toronto
search

1. Study Identification

Unique Protocol Identification Number
NCT02194595
Brief Title
Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
Acronym
PREVAIL
Official Title
Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
December 2021 (Actual)
Study Completion Date
February 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mount Sinai Hospital, Canada
Collaborators
Canadian Institutes of Health Research (CIHR), University of Toronto

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Type 2 diabetes mellitus is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). The investigators propose a randomized controlled trial to determine whether combining basal insulin with a new medication called exenatide is a therapeutic strategy that can preserve beta-cell function early in the course of type 2 diabetes.
Detailed Description
In this open-label, parallel-arm randomized controlled trial, adults with T2DM of ≤7 years duration on 0-2 anti-diabetic medications will be randomized to 8-weeks treatment with either (i) basal insulin glargine, (ii) intensive insulin therapy consisting of glargine and pre-meal insulin lispro, or (iii) glargine and the GLP-1 agonist exenatide (twice daily). They will then go into a 12-week washout on lifestyle modification only. Beta-cell function will be assessed by determining the Insulin Secretion-Sensitivity Index-2 (ISSI-2) on oral glucose tolerance test (OGTT) performed at baseline, 4-weeks, 8-weeks, and 20-weeks. The primary outcome will be mean beta-cell function (ISSI-2) over the 8-week treatment period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
type 2 diabetes, beta-cell function, GLP-1, insulin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
105 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Basal insulin and exenatide
Arm Type
Experimental
Arm Description
Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.
Arm Title
Basal insulin only
Arm Type
Active Comparator
Arm Description
Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.
Arm Title
Basal Insulin and bolus insulin
Arm Type
Active Comparator
Arm Description
Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.
Intervention Type
Drug
Intervention Name(s)
Basal insulin and exenatide
Other Intervention Name(s)
Basal insulin glargine, Exenatide
Intervention Type
Drug
Intervention Name(s)
Basal insulin only
Other Intervention Name(s)
Basal insulin glargine
Intervention Type
Drug
Intervention Name(s)
Basal insulin and bolus insulin
Other Intervention Name(s)
Basal insulin glargine, Pre-meal insulin lispro
Primary Outcome Measure Information:
Title
Mean beta-cell function over the 8-week treatment period, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2)
Description
ISSI-2 is an established measure of beta-cell function. ISSI-2 is defined as the product of (i) insulin secretion measured by the ratio of the area-under-the-insulin-curve to the area-under-the-glucose curve and (ii) insulin sensitivity measured by the Matsuda index. The primary outcome comparison is between the glargine/exenatide and glargine only arms.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Baseline-adjusted beta-cell function at 20 weeks
Description
The secondary outcome of baseline-adjusted beta-cell function at 20 weeks will be measured with the Insulin Secretion-Sensitivity Index-2 (ISSI-2)
Time Frame
20 weeks
Title
Baseline-adjusted glycemic control at 20 weeks
Description
The secondary outcome of baseline-adjusted glycemic control at 20 weeks will be assessed by A1c (glycated hemoglobin)
Time Frame
20 weeks
Title
Endothelial function at 8 weeks
Description
Endothelial function will be assessed as the digital endothelial vasomotor function in response to reactive hyperemia using pulse amplitude tonometry, which will be measured by the pulse amplitude response to hyperemia (PAT ratio)
Time Frame
8 weeks
Title
Baseline-adjusted glycemic control at 8 weeks
Description
Baseline-adjusted glycemic control at 8 weeks will be measured by A1c
Time Frame
8 weeks
Other Pre-specified Outcome Measures:
Title
Baseline-adjusted insulin sensitivity at 8 weeks
Description
Baseline-adjusted insulin sensitivity at 8 weeks will be measured by Matsuda index
Time Frame
8 weeks
Title
Baseline-adjusted insulin sensitivity at 20 weeks
Description
Baseline-adjusted insulin sensitivity at 20 weeks will be measured by Matsuda index
Time Frame
20 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and women between the ages of 30 and 80 years inclusive T2DM diagnosed by a physician ≤7 years prior to enrolment On 0-2 anti-diabetic medications, with no change in dose/regimen in the preceding 4 weeks A1c at screening between 5.5% and 9.0% inclusive if on anti-diabetic medications, or between 6.0% and 9.5% inclusive if on no oral anti-diabetic medication BMI ≥ 23 kg/m2 Negative pregnancy test at recruitment for all women with childbearing potential Exclusion Criteria: Current anti-diabetic treatment with insulin or a glucagon-like peptide-1 (GLP-1) agonist Type 1 diabetes or secondary forms of diabetes History of hypoglycemia unawareness or severe hypoglycemia requiring assistance Hypersensitivity to insulin, exenatide, or the formulations of these products Renal dysfunction as evidenced by estimated glomerular filtration rate (eGFR)<30 ml/min by Modification of Diet in Renal Disease (MDRD) formula History of pancreatitis Family or personal history of Multiple Endocrine Neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma (MTC) Personal history of non-familial medullary thyroid carcinoma (MTC) Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer) Unwillingness to perform capillary glucose monitoring at least 4 times a day during treatment Pregnancy or unwillingness to use reliable contraception. Women should not be planning pregnancy for the duration of the study or the first 3 months after the study. Reliable contraception includes birth control pill, intra-uterine device, abstinence, tubal ligation, partner vasectomy, or condoms with spermicide. Any factor likely to limit adherence to the protocol, in the opinion of investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ravi Retnakaran, MD
Organizational Affiliation
MOUNT SINAI HOSPITAL
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Sinai Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G1X5
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

We'll reach out to this number within 24 hrs